 There is also evidence that non cannabinoid components of the Cannabis secondary metabolome such as Myrcene activate TRPV1.TRPV1 is also expressed at high levels in the central nervous system and has been proposed as a target for treatment not only of pain but also for other conditions such as anxiety.Furthermore, TRPV1 appears to mediate long-term synaptic depression (LTD) in the hippocampus.